Display Settings:

Format

Send to:

Choose Destination
AIDS. 1997 Oct;11(12):F101-5.

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA.

Author information

  • 1Service des Maladies Infectieuses, Centre Hospitalier, Tourcoing, France.

Abstract

OBJECTIVE:

To assess the clinical and economic consequences of the use of protease inhibitors in the treatment of HIV infection.

DESIGN:

Multicentric, observational, retrospective cohort study.

SETTING:

Ten AIDS reference centres in France.

PATIENTS:

All patients followed in each centre from September 1995 through October 1996.

MAIN OUTCOME MEASURES:

AIDS-defining events, death, health-care resources use, administration of antiretroviral therapy.

RESULTS:

Data from 7749 patients in 10 centres showed a drop in hospitalization days by 35%, new AIDS cases by 35%, and deaths by 46%. In the same period, the proportion of patients receiving antiretrovirals rose from 36 to 53% including highly active antiretroviral therapy (HAART), which rose from 0.3 to 18%. Overall cost evaluation showed a slight increase of monthly treatment cost of US$ 12 per patient. Comparison of the three centres that used HAART earliest to the three centres that used it latest showed a clear benefit to early HAART with a drop in hospitalization days by 41%, new AIDS cases by 41% and deaths by 69%. The proportion of patients with HAART rose to 27% and monthly health-care cost decreased by US$ 248852 (i.e., by US$ 101 per patient per month). Late prescribing centres experienced a less marked effect with a drop in hospitalization days by 22%, new AIDS cases by 31%, and deaths by 32.5%. Proportion of patients with HAART rose to 12% and monthly health-care costs increased by US$ 113578 (i.e., by US$ 38 per patient per month).

CONCLUSIONS:

This study supports the extensive use of HAART in HIV-infected patients.

PMID:
9342061
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk